Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
Home - The Pharma Times | Pharma & Health Care News Portal
Thursday, April 25, 2024

Workshop on Key Challenges and Regulatory Compliances for Pharma & Life...

Tamil Nadu Technology Development & Promotion Centre of CII in partnership with Ecolab organizing the Workshop on Key Challenges and Regulatory Compliances for Pharma...

Power Foods That Will Help You Quit Smoking

By Mr Rohit Shelatkar, Vice President, Vitabiotics Ltd. Smoking is an exasperating habit to quit, but if you truly want to take charge of your...

Biotechnology

Surge in Avascular Necrosis of the Femoral Head in India Post-COVID: A Closer Look...

New Delhi, August 21, 2023: The COVID-19 pandemic has cast an unprecedented shadow over the world, disrupting lives and healthcare systems in ways we never...

IT & Software Support

Appointments

Shriram Vijayakumar appointed as CEO of IHH Healthcare India

New Delhi, March 10, 2021: Mr. Shriram Vijayakumar has been appointed as the Chief Executive Officer of IHH Healthcare India, effective 01 March 2021. Shriram...

Awards

Financial Results

Approvals

Clinical Trails

Phase III DECISION Trial of Nexavar® (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival...

Berlin, January 3, 2013 – Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase III trial of Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement in progression-free survival. The study, called DECISION, evaluated the efficacy and safety of Nexavar compared to placebo. The safety and tolerability were generally consistent with the known profile of Nexavar. Detailed efficacy and safety analysis from this study are expected to be presented at an upcoming medical meeting. Effective treatment options are urgently needed for patients with RAI-refractory differentiated thyroid cancer,” said Dimitris Voliotis, MD, Vice President, Global Clinical Development Oncology, Bayer HealthCare. “We are pleased that the results of this study demonstrate that Nexavar may provide a treatment option for these patients.

Bulk Drug

Health Care

Alternative Medicine

Eye Care

Asian eyelid Blepharoplasty: a trend among north eastern patients to create eyelid crease

By Dr. Parag Telang, Plastic & Reconstructive Surgeon and Director of Designer Bodyz Centre for advanced cosmetic surgery Among people who have an indistinct crease...

Seeing the world differently :Eye Donation Fortnight By Dr. Shibu Varkey- Dr. Shibu Varkey,...

The realm of ophthalmology stands witness to remarkable advancements in medical science that have revolutionized the treatment of visual impairments. However, amidst the array...

Dr Basu Eye Hospital organizes a Visionary Eye Health Camp at Modern Public School...

New Delhi, October 11, 2023 :  Dr. Basu Eye Hospital organized an eye camp at Modern Public School , Shalimar Bagh, in anticipation of...

Product News

Adore the Luxury of Natural Skin and Hair Care Products

New Delhi, May 16, 2019: We all long for beautiful skin and hair but it's only possible with natural and herbal ingredients that have been...

Media Partners

Spotlight

Investments

Packaging

Latest News

Dental Care

Tips to maintain oral health!

By Dr.MS Prasad, Dental Surgeon, Columbia Asia Referral Hospital Yeshwanthpur It has been said that a person’s real happiness begins from the plate and is...

Hospital Management

Drug Discovery & Development

Suppliers

Technology

Companies

Global Standards and Compliance on ISO/IEC Barcode Verification for Pharma as...

New Delhi, May 17, 2020: Major pharma companies have been working on the needs for marking their products and labelling them with appropriately selected...

BD launches Preventing Risks of Infections and Medication Errors in IV...

New Delhi, April 15, 2019: BD (Becton, Dickinson and Company), a leading global medical technology company, has launched a new patient safety program for...

Marketing

Our Partners

Machinery & Equipments